[go: up one dir, main page]

MX2016015248A - Compuestos imidazo[1,2-a]pirazin-1-il-benzamida para tratar atrofia muscular espinal. - Google Patents

Compuestos imidazo[1,2-a]pirazin-1-il-benzamida para tratar atrofia muscular espinal.

Info

Publication number
MX2016015248A
MX2016015248A MX2016015248A MX2016015248A MX2016015248A MX 2016015248 A MX2016015248 A MX 2016015248A MX 2016015248 A MX2016015248 A MX 2016015248A MX 2016015248 A MX2016015248 A MX 2016015248A MX 2016015248 A MX2016015248 A MX 2016015248A
Authority
MX
Mexico
Prior art keywords
muscular atrophy
spinal muscular
pyrazin
imidazo
treating spinal
Prior art date
Application number
MX2016015248A
Other languages
English (en)
Other versions
MX375925B (es
Inventor
Pinard Emmanuel
Ratni Hasane
Green Luke
Williamson Patrick
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2016015248A publication Critical patent/MX2016015248A/es
Publication of MX375925B publication Critical patent/MX375925B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

La presente invención proporciona compuestos de fórmula (I) en donde A, X1, X2, R1, R2, R3, R4 y R5 son como se describe en el presente documento, así como sales farmacéuticamente aceptables de los mismos. Además, la presente invención se refiere a la fabricación de los compuestos de fórmula (I), composiciones farmacéuticas que los comprenden y su uso como medicamentos para el tratamiento de la atrofia muscular espinal.
MX2016015248A 2014-06-25 2015-06-22 Compuestos imidazo[1,2-a]pirazin-1-il-benzamida para tratar atrofia muscular espinal. MX375925B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14173935 2014-06-25
PCT/EP2015/063894 WO2015197503A1 (en) 2014-06-25 2015-06-22 Imidazo[1,2-a]pyrazin-1yl-benzamide compounds for treating spinal muscular atrophy

Publications (2)

Publication Number Publication Date
MX2016015248A true MX2016015248A (es) 2017-02-23
MX375925B MX375925B (es) 2025-03-07

Family

ID=50980240

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016015248A MX375925B (es) 2014-06-25 2015-06-22 Compuestos imidazo[1,2-a]pirazin-1-il-benzamida para tratar atrofia muscular espinal.

Country Status (10)

Country Link
US (1) US9975900B2 (es)
EP (1) EP3160967B1 (es)
JP (1) JP6675334B2 (es)
KR (1) KR102565544B1 (es)
CN (1) CN106459067B (es)
BR (1) BR112016026951B1 (es)
CA (1) CA2952895C (es)
MX (1) MX375925B (es)
RU (1) RU2725979C2 (es)
WO (1) WO2015197503A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160045063A (ko) 2013-08-19 2016-04-26 에프. 호프만-라 로슈 아게 스크리닝 방법
HUE055031T2 (hu) 2015-12-10 2021-10-28 Ptc Therapeutics Inc Módszerek Huntington-kór kezelésére
JP7376471B2 (ja) 2017-06-05 2023-11-08 ピーティーシー セラピューティクス， インコーポレイテッド ハンチントン病を処置するための化合物
WO2019005993A1 (en) 2017-06-28 2019-01-03 Ptc Therapeutics, Inc. METHODS OF TREATING HUNTINGTON'S DISEASE
CN111182898B (zh) 2017-06-28 2024-04-16 Ptc医疗公司 用于治疗亨廷顿氏病的方法
WO2019099564A1 (en) * 2017-11-14 2019-05-23 Children's Medical Center Corporation Novel imidazopyrimidine compounds and uses thereof
JP7382316B2 (ja) 2017-11-14 2023-11-16 ザ チルドレンズ メディカル センター コーポレーション ヒト免疫応答をモジュレートするためのイミダゾピリミジンの使用
CN112135815A (zh) 2018-03-27 2020-12-25 Ptc医疗公司 用于治疗亨廷顿氏病的化合物
US11685746B2 (en) 2018-06-27 2023-06-27 Ptc Therapeutics, Inc. Heteroaryl compounds for treating Huntington's disease
JP7427252B2 (ja) 2018-06-27 2024-02-05 株式会社リボルナバイオサイエンス 脊髄性筋萎縮症の予防または治療剤
MX2020014315A (es) 2018-06-27 2021-05-27 Ptc Therapeutics Inc Compuestos de heteroarilo para tratar la enfermedad de huntington.
ES2983003T3 (es) 2018-06-27 2024-10-21 Ptc Therapeutics Inc Compuestos heterocíclicos y heteroarílicos para el tratamiento de la enfermedad de Huntington
EP3911652A1 (en) * 2019-01-18 2021-11-24 Biogen MA Inc. Imidazo[1,2-a]pyridinyl derivatives as irak4 inhibitors
WO2021007378A1 (en) 2019-07-11 2021-01-14 Ptc Therapeutics, Inc. Compounds for use in treating huntington's disease
KR20220159386A (ko) * 2020-02-28 2022-12-02 레믹스 테라퓨틱스 인크. 스플라이싱을 조절하기 위한 화합물 및 방법
AU2021272972A1 (en) 2020-05-13 2022-12-08 Chdi Foundation, Inc. HTT modulators for treating Huntington's disease
JP2024525580A (ja) * 2021-07-07 2024-07-12 バイオジェン・エムエイ・インコーポレイテッド Ｉｒａｋ４タンパク質の分解をターゲティングするための化合物
KR20240115832A (ko) 2021-11-17 2024-07-26 씨에이치디아이 파운데이션, 인코포레이티드 헌팅턴병을 치료하기 위한 htt 조절제
US20250122192A1 (en) * 2021-12-03 2025-04-17 Rgenta Therapeutics, Inc. 5-pyrimidinecarboxamide derivatives and methods of using the same
AR132351A1 (es) 2023-04-13 2025-06-18 Syngenta Crop Protection Ag Derivados de imidazo[1,2-a]pirazina

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005085252A1 (en) * 2004-03-04 2005-09-15 Biofocus Discovery Limited Imidazo ‘1,2-a’ pyrazine compounds which interact with protein kinases
WO2008154241A1 (en) * 2007-06-08 2008-12-18 Abbott Laboratories 5-heteroaryl substituted indazoles as kinase inhibitors
CA2821817A1 (en) * 2010-12-17 2012-06-21 Bayer Intellectual Property Gmbh Substituted 6-imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
EA029984B1 (ru) * 2011-12-30 2018-06-29 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Соединения для лечения спинальной мышечной атрофии
CA2873060A1 (en) * 2012-05-11 2013-11-14 Abbvie Inc. Nampt inhibitors
US9212209B2 (en) * 2012-07-13 2015-12-15 Indiana University Research And Technology Corporation Screening methods for spinal muscular atrophy
GB201212513D0 (en) * 2012-07-13 2012-08-29 Ucb Pharma Sa Therapeutic agents
WO2014078813A1 (en) * 2012-11-19 2014-05-22 Irm Llc Compounds and compositions for the treatment of parasitic diseases
MX363456B (es) * 2013-06-25 2019-03-25 Hoffmann La Roche Compuestos para tratar atrofia muscular espinal.

Also Published As

Publication number Publication date
RU2017102014A3 (es) 2019-01-22
CN106459067B (zh) 2019-05-31
CA2952895A1 (en) 2015-12-30
US20170197969A1 (en) 2017-07-13
JP6675334B2 (ja) 2020-04-01
JP2017520570A (ja) 2017-07-27
EP3160967A1 (en) 2017-05-03
RU2725979C2 (ru) 2020-07-08
KR20170018076A (ko) 2017-02-15
EP3160967B1 (en) 2019-05-08
CN106459067A (zh) 2017-02-22
US9975900B2 (en) 2018-05-22
RU2017102014A (ru) 2018-07-27
KR102565544B1 (ko) 2023-08-10
CA2952895C (en) 2023-09-26
MX375925B (es) 2025-03-07
BR112016026951A2 (es) 2017-08-15
WO2015197503A1 (en) 2015-12-30
BR112016026951B1 (pt) 2022-09-20

Similar Documents

Publication Publication Date Title
MX2016015248A (es) Compuestos imidazo[1,2-a]pirazin-1-il-benzamida para tratar atrofia muscular espinal.
CR20160518A (es) Compuestos para tratar atrofia muscular espinal
MX2018005890A (es) Composiciones para tratar atrofia muscular espinal.
CO2017013708A2 (es) Macrociclos peptídicos contra acinetobacter baumannii.
DOP2019000030A (es) Inhibidores de cdk2/4/6
MX2022012313A (es) Oxisteroles y metodos de uso de los mismos.
UY37272A (es) Piridinas sustituidas con heteroarilo y métodos de uso
UY37205A (es) Inhibidores de bromodominios
DOP2017000278A (es) Piridinas sustituidas y método de uso
MX2019012847A (es) Compuestos de c5-anilinoquinazolina y su uso en el tratamiento del cancer.
CU20190101A7 (es) Imidazopirimidinas diazabicíclicas sustituidas
UY34955A (es) 4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos
ECSP17069696A (es) Compuestos novedosos
NI201700052A (es) Diamino-quinoleína 2,4 sustituida como nuevos agentes anticancerígenos
UY36875A (es) Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades
SV2018005657A (es) "nuevos derivados de imidazo[4,5-b]piridina, un proceso para su preparacion y composiciones farmaceuticas que los contienen"
CY1120602T1 (el) [1,2,4]τριαζολο[4,3-β]πυριδαζινες για χρηση στη θεραπευτικη αντιμετωπιση πολλαπλασιαστικων ασθενειων
CO2018003756A2 (es) Derivados de éter cíclico de pirazolo[1,5-a]pirimidin-3-carboxiamida
UY31805A (es) Agonistas m1, composiciones farmacéuticas de los mismos, procesos para su preparacion y sus usos para el tratamiento del dolor
ECSP18056196A (es) Derivados de indano
ECSP099644A (es) Derivados de quinolina, composiciones farmacéuticas que los comprenden y el uso de tales en el tratamiento de enfermedades del sistema nervioso central y periférico

Legal Events

Date Code Title Description
FG Grant or registration